Journal Home
Search for

Volume 192, Issue 1, Pages 10-17 (1 July 2009)


View previous. 4 of 14 View next.

Acute lymphoblastic leukemias with normal karyotypes are not without genomic aberrations

Anu UsvasaloaCorresponding Author Informationemail address, Riikka Rätyb, Arja Harila-Saaric, Pirjo Koistinend, Eeva-Riitta Savolainene, Kim Vettenrantaa, Sakari Knuutilaf, Erkki Elonenb, Ulla M. Saarinen-Pihkalaa

Received 5 December 2008; received in revised form 17 February 2009; accepted 24 February 2009.

Abstract 

Current cytogenetic techniques have enabled more accurate definition of genetic aberrations in the lymphoblasts of patients with acute lymphoblastic leukemia (ALL), at least in most cases. Detecting the cryptic aberrations undetected by conventional cytogenetic methods is important for disease classification, evaluation of prognosis, and minimal residual disease follow-up. We have studied DNA copy number alterations of 27 adolescent ALL patients with normal (n=26) or failed (n=1) karyotype at diagnosis using microarray comparative genomic hybridization (CGH). Aberrations were detected in 85% of cases, deletions being more frequent (39 in 19 patients) than gains (14 in 10 patients). Deletions of 9p21.3 were the most common aberration, and 41% of deletions were cryptic and <5 Mb in size. We conclude that ALL without any form of genetic alteration probably does not exist. Microarray CGH is a powerful tool to reveal otherwise cryptic aberrations in adolescent ALL.

a Hospital for Children and Adolescents, University of Helsinki, P.O. Box 281, 00029 HUS, Helsinki, Finland

b Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland

c Department of Pediatrics, Oulu University Hospital, Oulu, Finland

d Department of Internal Medicine, Oulu University Hospital, Oulu, Finland

e Department of Clinical Chemistry, Oulu University Hospital, Oulu, Finland

f Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland

Corresponding Author InformationCorresponding author. Tel.: +358-40-5207446; fax: +358-9-47174707.

PII: S0165-4608(09)00133-2

doi:10.1016/j.cancergencyto.2009.02.015


View previous. 4 of 14 View next.